Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model

AZD9291 (osimertinib) is approved for standard care in patients with EGFR T790M-positive non-small cell lung cancer (NSCLC) after prior EGFR TKI progression. Furthermore, AZD9291 is now being evaluated as a first-line treatment for NSCLC patients with activation EGFR mutations. Based on previous exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Ku, Bo Mi, Choi, Moon Ki, Sun, Jong-Mu, Lee, Se-Hoon, Ahn, Jin Seok, Park, Keunchil, Ahn, Myung-Ju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895014/
https://www.ncbi.nlm.nih.gov/pubmed/29641535
http://dx.doi.org/10.1371/journal.pone.0194730

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895014/
https://www.ncbi.nlm.nih.gov/pubmed/29641535
http://dx.doi.org/10.1371/journal.pone.0194730

Ejemplares similares